Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated significant growth potential through its TissueCypher test, which experienced a remarkable 92% year-over-year increase in test volume in the second quarter of 2025, reflecting strong adoption and market demand. The company anticipates that the gastrointestinal sales force will reach maturity by the second half of 2025, further supporting revenue growth as the company continues to enhance gross margins, which for TissueCypher reached an impressive 77% in the third quarter. These fundamental metrics, along with the ongoing expansion of the sales force, position Castle Biosciences favorably for sustained financial performance and market share growth in the molecular diagnostics sector.

Bears say

Castle Biosciences Inc. faces a negative outlook primarily due to anticipated EV-to-estimated 2026/2027 revenue multiples for its dermatology and DecisionDx-UM tests being projected to be considerably lower than those for its TissueCypher product. Despite the company’s management indicating minimal clinician pushback during the Q3'24 call, a significant concern persists regarding the low levels of clinician awareness, particularly in the gastrointestinal space, which could hinder test adoption and revenue growth. Furthermore, while the stock may appear undervalued based on conservative estimates, the underlying penetration challenges for key tests suggest that financial performance may not improve as anticipated in the near term.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.